

Q3 FY16 Revenue Growth At 24.88% YoY

9M FY16 Revenue Growth At 6.49% YoY

Growth seen in Capsules Business

February 6, 2016, New Delhi: Sunil Healthcare Ltd, a leading manufacturer of Empty Hard Gelatin Capsules, has announced its Un-audited Financial Results for the Quarter and Nine Months ended 31st December 2015.

Key Financial Highlights:

| Rs. Million | Q3FY16 | Q3FY15 | YoY% | 9MFY16 | 9MFY15 | YoY% |
|---------------------------|---------------|---------------|---------------|---------------|---------------|---------------|
| Revenue | 250.57 | 200.65 | 24.88% | 587.49 | 551.69 | 6.49% |
| Capsules | 207.88 | 141.93 | 46.47% | 544.80 | 443.90 | 22.73% |
| Marketing of Food Product | 42.69 | 58.72 | -27.30% | 42.69 | 107.79 | -60.40% |
| EBITDA | 43.29 | 28.50 | 51.89% | 117.55 | 91.12 | 29.01% |
| EBITDA Margin | 17.28% | 14.20% | 308bps | 20.01% | 16.52% | 349bps |
| Profit Before Tax | 21.69 | 14.33 | 51.36% | 61.97 | 40.20 | 54.15% |
| PAT | 14.82 | 9.36 | 58.33% | 39.96 | 26.79 | 49.16% |
| PAT Margin | 5.91% | 4.66% | 125bps | 6.80% | 4.86% | 194bps |
| Cash PAT | 24.51 | 15.47 | 58.44% | 66.93 | 58.09 | 15.22% |
| Cash PAT Margin | 9.78% | 7.71% | 207bps | 11.39% | 10.53% | 86bps |

Q3 & 9M FY16 - Performance Highlights:

Revenues for Q3 FY16 stood at Rs. 250.57 Mn, a growth of 24.88% YoY while the same was Rs. 587.49 Mn for 9M FY16 a growth of 6.49% YoY. The growth was led by traction witnessed in Capsules division which recorded 22.73% growth YoY in 9M FY16.

EBITDA for Q3 FY16 was at Rs. 43.29 Mn, an increase of 51.89% YoY while the same was Rs. 117.55 Mn for 9M FY16 a growth of 29.01% YoY. EBITDA margin stood at 17.28% and 20.01% for Q3 FY16 and 9M FY16 respectively. Margin expansion was 308bps and 349 bps for Q3 FY16 and 9M FY16 respectively. The expansion in margin is attributed to operating leverage witnessed with increase in sales to existing as well as new geographies and customers.

Profit After Tax for Q3 FY16 was at Rs. 14.82mn, growth of 58.33% YoY while for 9M FY16 it stood at Rs. 39.96 Mn a growth of 49.16% YoY.

Commenting on the results, Mr. D. Gnanasekaran (CEO) said “We have reported a good Quarterly performance with 24.88% growth in Capsule business. It’s been a good period for us and we aim to consolidate and further optimize moving forward.”

Brownfield Expansion Update

On completion of our expansion phase, we enhanced our annual capacity from 7.7 billion to 10 billion capsules p.a. at our existing plant at Alwar, Rajasthan. With expansion completed in Q3FY16 we expect significant operating leverage to play out. In Q3 FY16, we have achieved a capacity utilization rate of 80% and expect to maintain momentum going forward.

Healthcare Leadership Awards 2015 – Six Sigma

We have received the prominent “**The Best Use of Six Sigma in Healthcare**” Award at the “**Healthcare Leadership Awards**” hosted by ABP News, November 2015 in Mumbai. This award is a reflection of SHL’s pursuit towards continually improving itself by making it more competitive in the market place. This recognition highlights our competitive strengths and our commitment to our business.

HPMC (Vegetarian /Cellulose Capsules) Launch Response

The response to our HPMC launch has been in line with our strategy and we are confident of improved performance and greater acceptability of our products in International markets. Supplies to International markets have commenced during the quarter and we expect to make inroads to many more international markets going forward.

About Sunil Healthcare Ltd

Sunil Healthcare Ltd, is the second largest manufacturer of Empty Hard Gelatin Capsules in India. A GoI recognized Star Export House, ~50% of revenues are from exports. With four decades of experience, and a strong brand equity “Sunloc”, the company is a preferred vendor for large pharmaceutical companies.

The company was the pioneer of Double lock and Triple lock technology in India. With a strong focus on R &D, the company is constantly innovating its product line to cater to the industry requirements.

For more information, please visit the company website www.sunilhealthcare.com

Safe harbor statement

Statements in this document relating to future status, events, or circumstances, including but not limited to statements about plans and objectives, the progress and results of research and development, potential project characteristics, project potential and target dates for project related issues are forward-looking statements based on estimates and the anticipated effects of future events on current and developing circumstances. Such statements are subject to numerous risks and uncertainties and are not necessarily predictive of future results. Actual results may differ materially from those anticipated in the forward-looking statements. The company assumes no obligation to update forward-looking statements to reflect actual results changed assumptions or other factors.

For Further Details, Please Contact

Company :

Sunil Healthcare Ltd.

CIN - L24302DL1973PLC189662

Mr. Pawan Rathi, Chief Financial Officer

cfo@sunilhealthcare.com

www.sunilhealthcare.com

Investor Relations Advisors :

Strategic Growth Advisors Pvt. Ltd.

CIN - U74140MH2010PTC204285

Mr. Shogun Jain / Ms. Sanjita Ghosh

+91 7738377756 / +91 7738359389

jshogun@sgapl.net / gsanjita@sgapl.net

www.sgapl.net